Tag results:

Industry & Policy News

New Trial of ‘Pill-on-a-Thread’ Brings Screening for Esophageal Cancer Closer

[University of Cambridge] The BEST4 trial launched at Addenbrooke’s Hospital was the final step to see if the capsule sponge, known as the pill-on-a-thread, can prevent oesophageal cancer when used to screen or monitor those most at risk of the disease.

NCI Grant Funds New Cancer Research Opportunities for UAB and Samford Students

[The University of Alabama at Birmingham] Elizabeth E. Brown, M.P.H., Ph.D. and Lalita Shevde-Samant, Ph.D., are co-leading a new research education program entitled University of Alabama at Birmingham Enhancing Research in Cancer-related Health Professions with support from the National Cancer Institute.

BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments

[Brainstorm Cell Therapeutics, Inc.] Brainstorm Cell Therapeutics Inc. provided an update on the grant and allowance of three patent applications for NurOwn® and NurOwn-Exosomes. The patent grants claims for an isolated population of mesenchymal stem cells for use in treating amyotrophic lateral sclerosis.

Fehniger Receives Grant for Trial of Immunotherapy against Melanoma

[Washington University in St.Louis] Todd A. Fehniger, MD, PhD, and colleagues have received $1.5 million from the Rising Tide Foundation for Cancer Research and the Melanoma Research Alliance.

Clinical Trial Begins for Novel Natural Killer Cell Therapy

[Cincinnati Children’s] Cincinnati Children’s is one of only a few centers in the nation to test a novel therapy that uses cytokine-induced memory-like natural killer cells from haploidentical donors to treat AML. This study is open to patients ages 12 to 45 years with relapsed or refractory AML who have not undergone bone marrow transplantation.

Opdualag Licensed for Patients with Advanced Melanoma

[Medicines and Healthcare Products Regulatory Agency] The Medicines and Healthcare products Regulatory Agency has approved the advanced melanoma medicine Opdualag (nivolumab-relatlimab) for patients from the age of twelve.

Popular